Here are the 10-Q quarterly reports from Wave Life Sciences Ltd. (WVE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow WVE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WVE filings page.
Wave Life Sciences, Inc. (WVE) reported third-quarter 2026 revenue of $13.158 million, compared with $7.608 million a year earlier, while net loss was $61.912 million versus $53.852 million. Revenue was recognized under the GSK collaboration agreement; the quarter included a $12.0 million milestone after GSK selected a candidate for its development pipeline.
As of September 30, cash, cash equivalents and marketable securities totaled $431.0 million; operating cash use for the first nine months was $173.277 million versus $153.717 million a year earlier. Management expects these resources to fund operations for at least the next 12 months from the financial statements’ issuance date. Interim WVE-007 obesity-trial data included a 14% placebo-adjusted reduction in visceral fat at six months after a single 240 mg dose. Planning is underway for a two-year WVE-006 registrational trial, with a one-year interim analysis to support potential accelerated approval based on AATD biomarkers. Wave expects additional WVE-007 and WVE-006 data and to file a WVE-008 clinical trial application in Q4 2026.
Wave Life Sciences Ltd. reported a net loss of $69,355 thousand for the three months ended June 30, 2026, on collaboration revenue of $2,272 thousand, as operating expenses reached $76,074 thousand driven by $51,293 thousand in research and development and $24,781 thousand in general and administrative costs. For the first six months of 2026, revenue was $40,518 thousand and net loss was $95,442 thousand. Management stated that cash, cash equivalents and marketable securities of $490.6 million as of June 30, 2026 are expected to fund operations for at least twelve months.
The company remains a clinical‑stage RNA medicines developer with lead programs in obesity (WVE‑007), alpha‑1 antitrypsin deficiency (WVE‑006), PNPLA3 I148M liver disease (WVE‑008), Duchenne muscular dystrophy and Huntington’s disease, all built on its PRISM platform. Wave recognized $2,272 thousand of GSK collaboration revenue in the quarter and has about $22.6 million of deferred revenue remaining. It regained full rights to WVE‑006, advanced multiple clinical trials, and plans additional data readouts in 2026. Structural steps include a court‑approved redomiciliation from Singapore to Delaware expected in August 2026 and an extension of its Lexington, Massachusetts manufacturing lease, which increased operating lease right‑of‑use assets and liabilities by approximately $30.0 million.
Wave Life Sciences reported first-quarter 2026 revenue of $38.2M, up from $9.2M a year earlier, mainly from its GSK collaboration, including recognition of remaining deferred revenue after regaining full rights to AATD candidate WVE-006.
Operating expenses rose to $69.5M, but the operating loss narrowed to $31.3M, and net loss improved to $26.1M or $0.13 per share, compared with a $46.9M loss or $0.29 per share a year ago.
Wave ended the quarter with $544.6M in cash and cash equivalents and expects this to fund operations for at least 12 months. The company highlighted progress across its RNA programs, including obesity candidate WVE-007, RNA editing programs WVE-006 and WVE-008, DMD therapy WVE-N531, and HD candidate WVE-003, and outlined plans to redomicile its parent entity from Singapore to Delaware.
Wave Life Sciences Ltd. reported Q3 2025 results. Revenue was $7.6 million, primarily from the GSK collaboration, against operating expenses of $64.0 million, resulting in a net loss of $53.9 million (basic and diluted loss per share $0.32). Other income contributed $2.5 million, mainly from interest.
Cash and cash equivalents totaled $196.2 million at September 30, 2025. Net cash used in operating activities for the first nine months was $153.7 million, partly offset by financing inflows including $42.6 million from the at-the-market equity program. Subsequent to quarter-end, the company received an additional $52.1 million in net ATM proceeds.
Deferred revenue was $58.2 million allocated to unsatisfied obligations, with $46.5 million current and $11.7 million long-term. The GSK collaboration recognized $7.6 million in Q3 revenue; a $10.0 million AATD milestone was acknowledged subsequent to quarter-end. Shareholders’ equity was $124.5 million. Ordinary shares outstanding were 167,181,784 as of November 7, 2025.